Скачать или смотреть China's Sinovac Vaccine Inadequate Against Omicron Variant, Study Finds

The vaccine made by Sinovac Biotech Ltd., one of the most widely used in the world, doesn’t provide sufficient antibodies in two doses to neutralize the omicron variant and boosters will likely be needed to improve protection, initial lab findings showed.

While the first two studies to be released on the Chinese shot and omicron diverged on how much the vaccine’s immune response is degraded, they both indicated the standard two-dose course would not be enough, raising uncertainty over a shot relied on by millions of people in China and the developing world to protect against Covid-19.

Among a group of 25 people vaccinated with two Coronavac doses, none showed sufficient antibodies in their blood serum to neutralize the omicron variant, said a statement from a team of researchers at the University of Hong Kong released late Tuesday night.

Subscribe to our YouTube channel: https://bit.ly/2TwO8Gm
Subscribe to our newest channel Quicktake Explained: https://bit.ly/3iERrup

Bloomberg Quicktake brings you live global news and original shows spanning business, technology, politics and culture. Make sense of the stories changing your business and your world.

To watch complete coverage on Bloomberg Quicktake 24/7, visit http://www.bloomberg.com/qt/live, or watch on Apple TV, Roku, Samsung Smart TV, Fire TV and Android TV on the Bloomberg app.

Have a story to tell? Fill out this survey for a chance to have it featured on Bloomberg Quicktake: https://cor.us/surveys/27AF30

Connect with us on…
YouTube:    / bloomberg  
Breaking News on YouTube:    / bloombergquicktakenews  
Twitter:   / quicktake  
Facebook:   / quicktake  
Instagram:   / quicktake